RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Key Ophthalmic Patent in Mexico
9/14/2012 9:27:27 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a patent in Mexico for the treatment of dry eye syndrome and glaucoma, among other medical indications, using Thymosin beta 4 (Tß4), or its isoforms and fragments, derivatives and analogs. The patent is projected to expire in July 2026. The Company has similar issued patents or pending applications in major countries throughout the world.